Neumora Therapeutics (NasdaqGS:NMRA) Q4 2025 Earnings call March 30, 2026 08:00 AM ET Company ParticipantsAlyssa Larios - Company RepresentativeBill Aurora - Chief Operating and Development OfficerBrian Abrahams - Global Managing Director and Sector Head of Healthcare ResearchDouglas Tsao - Managing Director of Equity ResearchHelen Rubinstein - VP of Investor Relations and Corporate StrategyJosh Pinto - PresidentMike Milligan - CFONick Brandon - Chief Scientific OfficerPaul Berns - CEOPoorna Kannan - Biotec ...

Neumora Therapeutics (NasdaqGS:NMRA) Q4 2025 Earnings call March 30, 2026 08:00 AM ET Company ParticipantsAlyssa Larios - Company RepresentativeBill Aurora - Chief Operating and Development OfficerBrian Abrahams - Global Managing Director and Sector Head of Healthcare ResearchDouglas Tsao - Managing Director of Equity ResearchHelen Rubinstein - VP of Investor Relations and Corporate StrategyJosh Pinto - PresidentJulian Pino - Biotechnology Equity Research Senior AssociateMike Milligan - CFONick Brandon - Ch ...

Neumora Therapeutics (NasdaqGS:NMRA) Q4 2025 Earnings call March 30, 2026 08:00 AM ET Speaker9Ladies and gentlemen, thank you for standing by. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. Please be advised that today's conference is being recorded. I would now like to turn the call over to Helen Rubenstein, Vice President of Investor Relations and Corporate Strategy at Neumora. Please go ahead.Speaker4Good afternoon, a ...

WASHINGTON, DC 20549 FORM 10-K (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO ___________ Commission File Number: 001-41802 NEUMORA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Dela ...

Exhibit 99.1 Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update New data for NMRA-511 supports unsurpassed clinical ef ect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies KOASTAL-2 and -3 fully enrolled in the first quarter of 2026; on track for topline readout in the second quarter of 2026 NMRA-898 selected as lead program in M4 franchise based on promising clinical results from ongoing Phase 1 study KEY PIPELINE HI ...

New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies KOASTAL-2 and -3 fully enrolled in the first quarter of 2026; on track for topline readout in the second quarter of 2026 NMRA-898 selected as lead program in M4 franchise based on promising clinical results from ongoing Phase 1 study Strong financial position with $182.5 million in cash, cash equivalents and marketable securities expected to support operations into the ...

Core Viewpoint - The Schall Law Firm is investigating claims against Neumora Therapeutics, Inc. (NASDAQ: NMRA) for potential violations of securities laws, focusing on whether the company made false or misleading statements or failed to disclose important information to investors [1][2]. Group 1 - The investigation is aimed at protecting the rights of investors who may have suffered losses due to the company's actions [2]. - Shareholders are encouraged to participate in the investigation and can contact the Schall Law Firm for more information [3]. - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [3].

WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Monday, March 30, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update. A live webcast of t ...

Core Insights - Neumora Therapeutics Inc (NASDAQ:NMRA) is highlighted as a promising penny stock by analysts, particularly due to its drug candidate NMRA-511 aimed at treating agitation in Alzheimer's disease patients [1][3] - The company presented positive results from a Phase 1b study at the Guggenheim Emerging Outlook: Biotech Summit 2026, indicating favorable safety and tolerability profiles, which may lead to higher dose testing in 2026 [2] Company Overview - Neumora Therapeutics is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focusing on treatments for brain diseases, neurodegenerative diseases, and neuropsychiatric disorders [3] - Leerink Partners initiated coverage on Neumora with an Outperform rating and a price target of $8, citing the company's diverse portfolio and the potential for several programs to succeed [3]

Alzheimer's Disease Agitation Data - NMRA-511 demonstrated a favorable safety profile with no somnolence or sedation and significant improvements in agitation, with placebo-adjusted CMAI total score changes of -2.6 and -2.1 at Weeks 6 and 8, respectively [2] - Patients with elevated anxiety showed improvements of -7.6 and -5.6 at the same weeks [2] - William Blair projects peak U.S. sales of NMRA-511 to reach $1.8 billion, indicating promising early data despite previous setbacks with the V1a receptor antagonist approach [2] Obesity Update - Positive Phase 2 data for NMRA-215 in obesity is anticipated by year-end 2026, which could be a significant inflection point for Neumora [3] - William Blair has incorporated value into the Neumora model for NMRA-215, estimating a 15% probability of success that could unlock a market opportunity exceeding $2 billion under conservative assumptions [3] Depression Assets - The KOASTAL-2/3 trials of monotherapy navacaprant in major depressive disorder are expected to report results in the second quarter of 2026 [4] - There is intrigue surrounding the update in the KOR antagonist space, although caution is advised regarding the de-risking value of navacaprant [4] - NMRA stock experienced a 7.50% increase, reaching $3.45 at the last check [4]